BioVaxys Announces Delay in Filing Annual Financial Statements

Vancouver, BC — March 3, 2026 — Leads & Copy — BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB:BVAXF) has announced that it could not file its annual financial statements by the prescribed deadline of February 28, 2026.

The Annual Filings include the company’s annual financial statements, management’s discussion and analysis, and required certifications for the year ended October 31, 2025.

BioVaxys stated that it and its auditor have been diligently working to complete the filings. The company expects the audit to be completed by April 28, 2026, with the annual filings completed as soon as possible thereafter.

The primary factor contributing to the delay was a late start to the audit due to changes in the company's accounting systems and processes.

As a result of the delay, BioVaxys filed an application to the British Columbia Securities Commission to approve a temporary management cease trade order (MCTO) under National Policy 12-203 – Management Cease Trade Orders (NP 12-203).

The MCTO was granted, effective March 3, 2026, prohibiting trading in securities of the company by CEO James Passin and CFO Christopher Cherry.

The company expects to file the Annual Filings by April 28, 2026. The MCTO will remain in effect until the filings are completed. BioVaxys confirms that it will comply with the alternative information guidelines required by NP 12-203 while the Annual Filings are outstanding. These guidelines require the company to issue bi-weekly default status reports in the form of news releases.

BioVaxys Technology Corp. is a biopharmaceuticals company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases.

The company's clinical-stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer.

BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer.

BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FSE: 5LB) and in the U.S. on the OTC Markets (OTCQB: BVAXF).

Source: BioVaxys Technology Corp.